Kalaris Therapeutics KLRS
NASDAQ KLRS
$2.02 -0.05 (-2.42%)
At close: Oct 21, 2026 · 4:00 PM EDT

Kalaris Therapeutics (KLRS) Receivables - Other (2019 - 2020)

Updated

Kalaris Therapeutics (KLRS) posted Receivables - Other of $169,000 for Q3 2020, down 52.3% from the prior quarter.

Analysis

Kalaris Therapeutics (KLRS) Receivables - Other (2019 - 2020) Analysis & Trends

At the end of FY2019, Kalaris Therapeutics' Receivables - Other came in at $298,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Kalaris Therapeutics 47.48 Mn -46.02 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 169,000.00
Jun 30, 2020 354,000.00
Dec 31, 2019 298,000.00
API Access

Kalaris Therapeutics Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=KLRS&period=max&api_key=YOUR_API_KEY